Heritage Investors Management Corp trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 176,424 shares of the company’s stock after selling 2,157 shares during the quarter. Johnson & Johnson makes up 1.5% of Heritage Investors Management Corp’s holdings, making the stock its 18th biggest holding. Heritage Investors Management Corp’s holdings in Johnson & Johnson were worth $22,768,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently modified their holdings of the company. Vanguard Group Inc increased its holdings in Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Vanguard Group Inc. increased its holdings in Johnson & Johnson by 1.5% in the third quarter. Vanguard Group Inc. now owns 213,433,449 shares of the company’s stock worth $29,490,100,000 after purchasing an additional 3,235,861 shares in the last quarter. Morgan Stanley increased its holdings in Johnson & Johnson by 6.3% in the third quarter. Morgan Stanley now owns 22,920,470 shares of the company’s stock worth $3,166,921,000 after purchasing an additional 1,352,484 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Johnson & Johnson by 2,178.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 649,040 shares of the company’s stock worth $83,759,000 after purchasing an additional 620,558 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. increased its holdings in Johnson & Johnson by 58.2% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 1,602,167 shares of the company’s stock worth $221,371,000 after purchasing an additional 589,288 shares in the last quarter. Institutional investors own 66.91% of the company’s stock.
A number of equities research analysts have weighed in on JNJ shares. Zacks Investment Research upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 target price for the company in a report on Wednesday, March 27th. Morgan Stanley lifted their target price on Johnson & Johnson from $134.00 to $145.00 and gave the stock an “equal weight” rating in a report on Wednesday, April 17th. Barclays reiterated an “equal weight” rating and issued a $135.00 target price (down from $137.00) on shares of Johnson & Johnson in a report on Wednesday, January 23rd. Citigroup lifted their target price on Johnson & Johnson from $139.00 to $147.00 and gave the stock a “neutral” rating in a report on Monday, February 25th. Finally, Wells Fargo & Co restated an “outperform” rating and set a $157.00 price objective (up previously from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Johnson & Johnson has an average rating of “Buy” and a consensus price target of $146.90.
NYSE JNJ opened at $136.91 on Thursday. The company has a market cap of $368.09 billion, a PE ratio of 16.74, a PEG ratio of 2.37 and a beta of 0.67. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.03 by $0.07. The firm had revenue of $20.02 billion during the quarter, compared to the consensus estimate of $19.55 billion. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The company’s quarterly revenue was up .1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.06 earnings per share. On average, equities analysts anticipate that Johnson & Johnson will post 8.6 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Tuesday, May 28th will be issued a dividend of $0.95 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. The ex-dividend date is Friday, May 24th. This represents a $3.80 annualized dividend and a dividend yield of 2.78%. Johnson & Johnson’s payout ratio is currently 44.01%.
TRADEMARK VIOLATION NOTICE: This article was originally posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thelincolnianonline.com/2019/05/16/heritage-investors-management-corp-has-22-77-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Article: Should you buy a closed-end mutual fund?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.